10.1007/s40089-015-0161-8

Development of nanostructured lipid carrier for dacarbazine delivery

HTML PDF
  • Musallam Almousallam1,
  • Claudia Moia1,
  • Huijun Zhu*1,
  1. Institute of Environment, Health, Risks and Futures, Cranfield University, Bedfordshire, MK43 0AL, GB
Cover Image

Published in Issue 2015-09-21

How to Cite

Almousallam, M., Moia, C., & Zhu, H. (2015). Development of nanostructured lipid carrier for dacarbazine delivery. International Nano Letters, 5(4 (December 2015). https://doi.org/10.1007/s40089-015-0161-8
Crossref
Scopus
Google Scholar
Europe PMC

HTML views: 14

PDF views: 71

Abstract

Abstract Dacarbazine (Dac) is one of the most commonly used chemotherapy drugs for treating various cancers. However, its poor water solubility, short half-life in blood circulation, low response rate and high side effect limit its application. This study aimed to improve the drug solubility and prolong drug release by developing nanostructured lipid carriers (NLCs) for Dac delivery. The NLC and Dac-encapsulated NLC were synthesized with precirol ATO 5 and isopropyl myristate as lipids, tocopheryl polyethylene glycol succinate, soybean lecithin and Kolliphor P 188 as co-surfactants. The NLCs with controlled size were achieved using high shear dispersion following solidification of oil-in-water emulsion. For Dac encapsulation, the smallest NLC with 155 ± 10 nm in size, 0.2 ± 0.01 polydispersion index and −43.4 ± 2 mV zeta potential was selected. The resultant DLC-Dac possessed size, polydispersion index and zeta potential of 190 ± 10, 0.2 ± 0.01, and −43.5 ± 1.2, respectively. The drug encapsulation efficiency and drug loading were 98.5 % and 14 %, respectively. In vitro drug release study showed a biphasic pattern, with 50 % released in the first 2 h, and the remaining released sustainably for up to 30 h. This is the first report on the development of NLC for Dac delivery, implying that NLC could be a new potential candidate as drug carrier to improve the therapeutic profile of Dac.

Keywords

  • Nanostructured lipid carrier,
  • Dacarbazine,
  • High shear dispersion,
  • Drug delivery
HTML PDF

References

  1. Sun et al. (2014) Quercetin-nanostructured lipid carriers: characteristics and anti-breast cancer activities in vitro (pp. 15-24) https://doi.org/10.1016/j.colsurfb.2013.08.032
  2. Eigentler et al. (2003) Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials 4(12) (pp. 748-759) https://doi.org/10.1016/S1470-2045(03)01280-4
  3. Jerant et al. (2000) Early detection and treatment of skin cancer 62(2) (pp. 357-368)
  4. Quirin et al. (2007) Combining adenoviral oncolysis with temozolomide improves cell killing of melanoma cells 121(12) (pp. 2801-2807) https://doi.org/10.1002/ijc.23052
  5. Lens and Dawes (2004) Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma 150(2) (pp. 179-185) https://doi.org/10.1111/j.1365-2133.2004.05708.x
  6. Chen et al. (2013) Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics (pp. 2677-2688) https://doi.org/10.2147/IJN.S45429
  7. Ohshio et al. (1998) Gastrinoma with multiple liver metastases: effectiveness of dacarbazine (DTIC) therapy 5(3) (pp. 339-343) https://doi.org/10.1007/s005340050056
  8. Loo et al. (1976) Mechanism of action and pharmacology studies with DTIC (NSC 45388) 60(2) (pp. 149-152)
  9. Gerulath and Loo (1972) Mechanism of action of 5-(3,3-dimethyl-1-triazeno)imidazole-4-caboxamide in mammalian cells in culture 21(17) (pp. 2335-2343) https://doi.org/10.1016/0006-2952(72)90384-X
  10. Bedia et al. (2011) Acid ceramidase expression modulates the sensitivity of A375 melanoma cells to dacarbazine 286(32) (pp. 28200-28209) https://doi.org/10.1074/jbc.M110.216382
  11. Breithaupt et al. (1982) Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules 9(2) (pp. 103-109) https://doi.org/10.1007/BF00265388
  12. Chapman et al. (1999) Phase III multicenter randomized trial of the dartmouth regimen versus dacarbazine in patients with metastatic melanoma 17(9) (pp. 2745-2751)
  13. Luikart et al. (1984) Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma 2(3) (pp. 164-168)
  14. Eggermont and Kirkwood (2004) Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? 40(12) (pp. 1825-1836) https://doi.org/10.1016/j.ejca.2004.04.030
  15. Soengas and Lowe (2003) Apoptosis and melanoma chemoresistance 22(20) (pp. 3138-3151) https://doi.org/10.1038/sj.onc.1206454
  16. Bei et al. (2010) Formulation of dacarbazine-loaded cubosomes. Part III. Physicochemical characterization 11(3) (pp. 1243-1249) https://doi.org/10.1208/s12249-010-9496-7
  17. Ding et al. (2011) Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity (pp. 1991-2005)
  18. Ding et al. (2011) Biodegradable methoxy poly (ethylene glycol)-poly (lactide) nanoparticles for controlled delivery of dacarbazine: preparation, characterization and anticancer activity evaluation 5(11) (pp. 1369-1377) https://doi.org/10.5897/AJPP11.236
  19. Kakumanu et al. (2011) A nanoemulsion formulation of dacarbazine reduces tumor size in a xenograft mouse epidermoid carcinoma model compared to dacarbazine suspension 7(3) (pp. 277-283) https://doi.org/10.1016/j.nano.2010.12.002
  20. Taratula et al. (2013) Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA 171(3) (pp. 349-357) https://doi.org/10.1016/j.jconrel.2013.04.018
  21. Müller et al. (2002) Nanostructured lipid matrices for improved microencapsulation of drugs 242(1–2) (pp. 121-128) https://doi.org/10.1016/S0378-5173(02)00180-1
  22. Patidar et al. (2010) A review on novel lipid based nanocarriers 2(4) (pp. 30-35)
  23. Alam et al. (2014) Pharmacoscintigraphic evaluation of potential of lipid nanocarriers for nose-to-brain delivery of antidepressant drug 470(1–2) (pp. 99-106) https://doi.org/10.1016/j.ijpharm.2014.05.004
  24. Gonzalez-Mira et al. (2011) Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery 22(4) (pp. 45101-45115) https://doi.org/10.1088/0957-4484/22/4/045101
  25. Pardeike et al. (2009) Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products 366(1–2) (pp. 170-184) https://doi.org/10.1016/j.ijpharm.2008.10.003
  26. Pardeike et al. (2011) Development of an Itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application 419(1–2) (pp. 329-338) https://doi.org/10.1016/j.ijpharm.2011.07.040
  27. Irfan et al. (2014) Assessment of temporal dose-toxicity relationship of fumed silica nanoparticle in human lung A549 cells by conventional cytotoxicity and 1H-NMR-based extracellular metabonomic assays 138(2) (pp. 354-364) https://doi.org/10.1093/toxsci/kfu009
  28. Neupane et al. (2014) Lipid based nanocarrier system for the potential oral delivery of decitabine: formulation design, characterization, ex vivo, and in vivo assessment 477(1–2) (pp. 601-612) https://doi.org/10.1016/j.ijpharm.2014.11.001
  29. Lim et al. (2014) Formulation and delivery of itraconazole to the brain using a nanolipid carrier system 9(1) (pp. 2117-2126) https://doi.org/10.2147/IJN.S57565
  30. Puglia et al. (2014) Evaluation of nanostructured lipid carriers (NLC) and nanoemulsions as carriers for UV-filters: characterization, in vitro penetration and photostability studies 51(1) (pp. 211-217) https://doi.org/10.1016/j.ejps.2013.09.023
  31. Riddick (1968) Zeta-Meter Inc.
  32. Kullavadee et al. (2012) Effect of surfactant on characteristics of solid lipid nanoparticles (SLN) (pp. 313-316) https://doi.org/10.4028/www.scientific.net/AMR.364.313
  33. Leonardi et al. (2014) Influence of different surfactants on the technological properties and in vivo ocular tolerability of lipid nanoparticles 470(1) (pp. 133-140) https://doi.org/10.1016/j.ijpharm.2014.04.061
  34. Bei et al. (2009) Formulation of dacarbazine-loaded cubosomes—part I: influence of formulation variables 10(3) (pp. 1032-1039) https://doi.org/10.1208/s12249-009-9293-3
  35. Song et al. (2014) Improved skin delivery of voriconazole with a nanostructured lipid carrier-based hydrogel formulation 62(8) (pp. 793-798) https://doi.org/10.1248/cpb.c14-00202
  36. Mu and Feng (2002) Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel 80(1) (pp. 129-144) https://doi.org/10.1016/S0168-3659(02)00025-1
  37. Zhou et al. (2012) Preparation of tripterine nanostructured lipid carriers and their absorption in rat intestine 67(4) (pp. 304-310)
  38. Wissing and Müller (2003) Cosmetic applications for solid lipid nanoparticles (SLN) 254(1) (pp. 65-68) https://doi.org/10.1016/S0378-5173(02)00684-1
  39. Lei et al. (2015) Dual drug encapsulation in a novel nano-vesicular carrier for the treatment of cutaneous melanoma: characterization and in vitro/in vivo evaluation 5(26) (pp. 20467-20478) https://doi.org/10.1039/C4RA16306K